The knockdown of HNRNPA2B1 impedes the association of oTau or tau oligomers with m6A, prevents the reduction of protein synthesis, and attenuates oTau-induced neurodegeneration.152 In addition, HNRNPA2B1 promotes the progression of multiple myeloma by stabilizing interleukin enhancer-binding factor 3 mRNA through m6A recognition and regulating AKT3 expression, underscoring its potential as a therapeutic target.153 In summary, HNRNPA2B1 emerges as a promising therapeutic target and biomarker for future clinical applications. The gene discussed is HNRNPA2B1; the disease is plasma cell myeloma.